COMP <GO>
GH vs JNJ // FORWARD P/E MULTIPLE
Guardant Health Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: GH 3
— JNJ 10
▲ FORWARD P/E MULTIPLE LEADER: GH
LAST: $178.80 (-3.51%) • MKT CAP: $24.87B
forward-pe
19.0x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.50% | 67.90% | -3.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | 25.50% | -42.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 2.97% | -3.91 | JNJ | /fcf-yield <GO> |
| Operating Margin | -44.50% | 34.70% | -79.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -42.40% | 28.50% | -70.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 6.00% | +26.90 | GH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.44 | 5.59 | -0.15 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | GH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 60.4 | -3.10 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.08 | -0.21 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 19.0x | 23.0x | -4.00 | GH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.87B | $662.49B | -$637.62B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GH REV | JNJ REV | GH GROSS % | JNJ GROSS % | GH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $94.19B | 64.5% | 67.9% | -$233.1M | $19.70B |
| FY 2024 | $739.0M | $88.82B | 60.8% | 69.1% | -$274.9M | $19.84B |
| FY 2023 | $563.9M | $85.16B | 44.0% | 44.0% | -$350.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
JNJ // BETA 1.08